CN103906756B - 用于治疗疾病的方法 - Google Patents

用于治疗疾病的方法 Download PDF

Info

Publication number
CN103906756B
CN103906756B CN201280053322.1A CN201280053322A CN103906756B CN 103906756 B CN103906756 B CN 103906756B CN 201280053322 A CN201280053322 A CN 201280053322A CN 103906756 B CN103906756 B CN 103906756B
Authority
CN
China
Prior art keywords
administered
patient
superoxide dismutase
dismutase mimetic
over
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280053322.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103906756A (zh
Inventor
J·L·基恩
D·P·赖利
R·A·比尔兹利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galera Therapeutics LLC
Original Assignee
Galera Labs LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galera Labs LLC filed Critical Galera Labs LLC
Priority to CN202010082500.XA priority Critical patent/CN111467351A/zh
Publication of CN103906756A publication Critical patent/CN103906756A/zh
Application granted granted Critical
Publication of CN103906756B publication Critical patent/CN103906756B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
CN201280053322.1A 2011-09-26 2012-09-24 用于治疗疾病的方法 Active CN103906756B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010082500.XA CN111467351A (zh) 2011-09-26 2012-09-24 用于治疗疾病的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161539365P 2011-09-26 2011-09-26
US61/539,365 2011-09-26
PCT/US2012/056921 WO2013048965A1 (en) 2011-09-26 2012-09-24 Methods for treatment of diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010082500.XA Division CN111467351A (zh) 2011-09-26 2012-09-24 用于治疗疾病的方法

Publications (2)

Publication Number Publication Date
CN103906756A CN103906756A (zh) 2014-07-02
CN103906756B true CN103906756B (zh) 2020-03-03

Family

ID=47911939

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280053322.1A Active CN103906756B (zh) 2011-09-26 2012-09-24 用于治疗疾病的方法
CN202010082500.XA Pending CN111467351A (zh) 2011-09-26 2012-09-24 用于治疗疾病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010082500.XA Pending CN111467351A (zh) 2011-09-26 2012-09-24 用于治疗疾病的方法

Country Status (8)

Country Link
US (5) US9149483B2 (enExample)
EP (1) EP2760874A4 (enExample)
JP (6) JP6267638B2 (enExample)
CN (2) CN103906756B (enExample)
AU (5) AU2012316397B2 (enExample)
CA (2) CA2849456C (enExample)
HK (1) HK1199261A1 (enExample)
WO (1) WO2013048965A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2056675T (pt) 2006-10-12 2019-05-09 Galera Labs Llc Métodos de tratamento da mucosite oral
CN103906756B (zh) 2011-09-26 2020-03-03 加莱拉实验室有限责任公司 用于治疗疾病的方法
TWI746449B (zh) * 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
JP7041959B2 (ja) * 2015-08-11 2022-03-25 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー 経口バイオアベイラビリティを有するペンタアザ大環状環錯体
WO2017192740A2 (en) 2016-05-03 2017-11-09 Galera Labs, Llc Combination therapy for cancer treatment
AU2017318718B2 (en) * 2016-09-01 2023-06-29 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
US20210361701A1 (en) * 2017-02-15 2021-11-25 Galera Labs, Llc Pentaaza macrocyclic ring complexes for local delivery
IL295620B2 (en) 2017-04-13 2024-01-01 Galera Labs Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
US20210338686A1 (en) * 2018-01-31 2021-11-04 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
WO2021072359A1 (en) * 2019-10-10 2021-04-15 Galera Labs, Llc Manufacture method for aqueous formulation of manganese-containing coordination complex, formulation and method of treatment
EP4103573A1 (en) * 2020-02-13 2022-12-21 Teva Pharmaceuticals International GmbH Solid state forms of avasopasem manganese and process for preparation thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1200039A (zh) * 1995-08-17 1998-11-25 孟山都公司 可用作岐化超氧化物催化剂的、含氮大环配体的锰配合物的生物结合物
EP1185312B1 (en) * 1999-05-27 2005-03-23 Monsanto Company Biomaterials modified with superoxide dismutase mimics
CN1620325A (zh) * 2001-12-14 2005-05-25 艾尔科公司 治疗眼睛障碍和疾病的超氧化物歧化酶模拟物
CN1636007A (zh) * 2000-11-28 2005-07-06 优卡里昂股份有限公司 环状salen－金属化合物：在疾病治疗和预防中用作抗氧化剂的活性氧清除剂
WO2009143454A2 (en) * 2008-05-22 2009-11-26 Kereos, Inc. Combination antitumor therapy
EP2312309A2 (en) * 2001-03-02 2011-04-20 MetaPhore Pharmaceuticals, Inc. Chromatography of metal complexes

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001212A (en) 1973-10-03 1977-01-04 E. I. Du Pont De Nemours And Company Macrocyclic polyamines
US3930867A (en) 1974-01-07 1976-01-06 E. I. Du Pont De Nemours And Company Macrocyclic polyamines as sensitizers for silver halide emulsions
JPS61226751A (ja) 1985-03-30 1986-10-08 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料用処理液及びその処理方法
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5096724A (en) 1988-06-03 1992-03-17 Aquanautics Corporation Methods, compositions, and systems for ligand extraction
GB9001245D0 (en) 1990-01-19 1990-03-21 Salutar Inc Compounds
JP3155552B2 (ja) 1991-07-19 2001-04-09 モンサント カンパニー 超酸化物の不均斉変化に有効な触媒としての窒素含有−大環状リガンドのマンガン錯体
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
WO1995028968A1 (en) 1994-04-22 1995-11-02 Monsanto Company Diagnostic image analysis with metal complexes
US6245758B1 (en) 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
JPH0840941A (ja) 1994-07-29 1996-02-13 Kanegafuchi Chem Ind Co Ltd 炎症性腸疾患治療製剤
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
AU6722496A (en) 1995-08-17 1997-03-12 Monsanto Company Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands
EP0846003A1 (en) 1995-08-17 1998-06-10 Monsanto Company Methods of diagnostic image analysis using bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands
US20050171198A1 (en) 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
US6180620B1 (en) * 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
US20020128248A1 (en) 1997-06-20 2002-09-12 Metaphore Pharmaceuticals, Inc SODm therapy for prevention and/or treatment of inflammatory disease
US6214817B1 (en) * 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US20060270639A1 (en) 1997-06-20 2006-11-30 Daniela Salvemini Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
JP2991172B2 (ja) 1997-10-24 1999-12-20 日本電気株式会社 半導体装置
ES2198767T3 (es) 1997-11-03 2004-02-01 Duke University Porfirinas sustituidas.
GB9817845D0 (en) 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
US6040330A (en) 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
AU761674B2 (en) 1999-06-23 2003-06-05 Eric F. Bernstein Use of nitroxides in wound healing and in the prevention of photodamage
EP2343047B2 (en) 2000-02-08 2021-03-17 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
WO2002017887A1 (de) 2000-08-29 2002-03-07 Mepha Ag Arzneimittel zur behandlung von darmerkrankungen
US7166910B2 (en) 2000-11-28 2007-01-23 Knowles Electronics Llc Miniature silicon condenser microphone
US20020072512A1 (en) 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
US20050175580A1 (en) 2001-01-05 2005-08-11 Daniela Salvemini Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
AU2002248366B2 (en) * 2001-01-19 2006-10-26 Aeolus Sciences, Inc. Cancer therapy
EP1353655A2 (en) 2001-01-26 2003-10-22 Metaphore Pharmaceuticals Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
US20040137638A1 (en) 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
WO2002100395A1 (en) 2001-06-08 2002-12-19 Genzyme Corporation Bismuth salts of anti-oxidants and radical scavengers for prevention and treatment of mucous membrane ulcers
US20040132706A1 (en) 2001-10-05 2004-07-08 Daniela Salvemini Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension
IL161686A0 (en) 2001-11-01 2004-09-27 Uab Research Foundation Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
AU2003229923A1 (en) 2002-04-16 2003-11-03 Isis Innovation Limited Curcumin for the prevention and/or treatment of tissue damage
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
US6781231B2 (en) 2002-09-10 2004-08-24 Knowles Electronics Llc Microelectromechanical system package with environmental and interference shield
US6798047B1 (en) 2002-12-26 2004-09-28 Amkor Technology, Inc. Pre-molded leadframe
WO2005042718A2 (en) 2003-10-31 2005-05-12 Metaphore Pharmaceuticals, Inc. Compositions and methods for treating, preventing, reversing and inhibiting pain
FR2863892B1 (fr) 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
US7510710B2 (en) 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
MXPA06011244A (es) 2004-03-29 2007-04-13 Inotek Pharmaceuticals Corp Compuestos de porfirina sustituida por piridilo, y metodos de uso de los mismos.
US7262498B2 (en) 2004-10-19 2007-08-28 Hewlett-Packard Development Company, L.P. Assembly with a ring and bonding pads formed of a same material on a substrate
US20070148154A1 (en) 2004-12-17 2007-06-28 Universite Rene Descartes (Paris V) Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs
US8217166B2 (en) 2005-05-05 2012-07-10 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
WO2006083508A2 (en) 2005-01-10 2006-08-10 Metaphore Pharmaceuticals Inc. Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
US20090099150A1 (en) 2005-01-19 2009-04-16 Daniela Salvemini Methotrexate Combinations For Treating Inflammatory Diseases
AR053566A1 (es) 2005-03-31 2007-05-09 Schering Corp Compuestos espiriciclicos antagonistas de los receptores de trombina
CN2870352Y (zh) 2005-12-23 2007-02-14 瑞声声学科技(深圳)有限公司 微机电系统传声器扣合式封装结构
US20100158857A1 (en) 2006-05-23 2010-06-24 University Of Utah Research Foundation Compositions and methods for the inhibition of endothelial nitric oxide synthase activity
WO2008027547A2 (en) 2006-08-31 2008-03-06 The Brigham And Women's Hospital, Inc. Antioxidant therapies
WO2008033466A2 (en) 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
PT2056675T (pt) 2006-10-12 2019-05-09 Galera Labs Llc Métodos de tratamento da mucosite oral
TWI333264B (en) 2007-01-10 2010-11-11 Advanced Semiconductor Eng Packaging structure and method of mems microphone
WO2009033726A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of cart (55-102), optionally in combination with tuftsin, as a therapeutic agent
JP5579083B2 (ja) * 2008-02-29 2014-08-27 イーグル・ファーマシューティカルズ・インコーポレーテッド そのまま使用できるトポテカン溶液
WO2009134616A2 (en) 2008-04-15 2009-11-05 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
TW201134481A (en) 2010-03-12 2011-10-16 Abbott Biotherapeutics Corp CTLA4 proteins and their uses
US20120207687A1 (en) 2011-01-14 2012-08-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Topical formulations of targeted nitroxide agents
CN103906756B (zh) 2011-09-26 2020-03-03 加莱拉实验室有限责任公司 用于治疗疾病的方法
US9238659B2 (en) 2012-11-19 2016-01-19 The University Of Hong Kong Method of using binuclear gold (I) compounds for cancer treatment
JP7041959B2 (ja) 2015-08-11 2022-03-25 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー 経口バイオアベイラビリティを有するペンタアザ大環状環錯体
WO2017192740A2 (en) 2016-05-03 2017-11-09 Galera Labs, Llc Combination therapy for cancer treatment
AU2017318718B2 (en) 2016-09-01 2023-06-29 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
WO2018125862A1 (en) 2016-12-27 2018-07-05 Soon Kap Hahn Prevention of local tumor recurrence following surgery using sustained and/or delayed release of medicaments contained in micro-particles
US20210361701A1 (en) 2017-02-15 2021-11-25 Galera Labs, Llc Pentaaza macrocyclic ring complexes for local delivery
IL295620B2 (en) 2017-04-13 2024-01-01 Galera Labs Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
SG11201909495PA (en) 2017-04-13 2019-11-28 Galera Labs Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
US20210338686A1 (en) 2018-01-31 2021-11-04 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1200039A (zh) * 1995-08-17 1998-11-25 孟山都公司 可用作岐化超氧化物催化剂的、含氮大环配体的锰配合物的生物结合物
EP1185312B1 (en) * 1999-05-27 2005-03-23 Monsanto Company Biomaterials modified with superoxide dismutase mimics
CN1636007A (zh) * 2000-11-28 2005-07-06 优卡里昂股份有限公司 环状salen－金属化合物：在疾病治疗和预防中用作抗氧化剂的活性氧清除剂
EP2312309A2 (en) * 2001-03-02 2011-04-20 MetaPhore Pharmaceuticals, Inc. Chromatography of metal complexes
CN1620325A (zh) * 2001-12-14 2005-05-25 艾尔科公司 治疗眼睛障碍和疾病的超氧化物歧化酶模拟物
WO2009143454A2 (en) * 2008-05-22 2009-11-26 Kereos, Inc. Combination antitumor therapy
EP2296645B1 (en) * 2008-05-22 2014-11-19 Galera Therapeutics, LLC Combination antitumor therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Metaphore Pharmaceuticals：Mimicking Nature’s Enzyme;Alice;《Chemistry & Biology》;20031231;第10卷;第1139–1140页 *

Also Published As

Publication number Publication date
JP2020183416A (ja) 2020-11-12
WO2013048965A1 (en) 2013-04-04
US11826373B2 (en) 2023-11-28
JP6267638B2 (ja) 2018-01-24
JP7697688B2 (ja) 2025-06-24
CA2849456A1 (en) 2013-04-04
JP2025131753A (ja) 2025-09-09
EP2760874A4 (en) 2015-04-08
US20220088030A1 (en) 2022-03-24
JP2018035162A (ja) 2018-03-08
JP2023027289A (ja) 2023-03-01
AU2020244613A1 (en) 2020-11-05
AU2016247160A1 (en) 2016-11-10
US10493081B2 (en) 2019-12-03
AU2020244613C1 (en) 2023-09-28
US10137133B2 (en) 2018-11-27
AU2012316397A1 (en) 2014-03-13
CA2849456C (en) 2021-12-07
US20190240233A1 (en) 2019-08-08
AU2019201392A1 (en) 2019-03-21
AU2016247160B2 (en) 2018-12-06
US20160151383A1 (en) 2016-06-02
AU2019201392B2 (en) 2020-10-08
US20250017944A1 (en) 2025-01-16
CA3120505A1 (en) 2013-04-04
CN103906756A (zh) 2014-07-02
US9149483B2 (en) 2015-10-06
JP2018184465A (ja) 2018-11-22
AU2020244613B2 (en) 2023-01-05
CA3120505C (en) 2024-11-12
AU2023201978A1 (en) 2023-05-04
US20130079317A1 (en) 2013-03-28
JP6736618B2 (ja) 2020-08-05
JP2014526562A (ja) 2014-10-06
EP2760874A1 (en) 2014-08-06
AU2012316397B2 (en) 2016-07-21
JP6382416B2 (ja) 2018-08-29
JP7562125B2 (ja) 2024-10-07
HK1199261A1 (en) 2015-06-26
CN111467351A (zh) 2020-07-31

Similar Documents

Publication Publication Date Title
CN103906756B (zh) 用于治疗疾病的方法
JP2022107687A (ja) ペメトレキセドまたはその薬剤学的に許容可能な塩を含有する安定化された薬学組成物
KR20200052326A (ko) 코판리십의 제제
KR101807462B1 (ko) 보르테조밉을 포함하는 안정한 제제 및 이의 제조방법
US20170035831A1 (en) Composition comprising bortezomib
JP2019502751A5 (enExample)
EP3498266A1 (en) Formulations of copanlisib
JP6549107B2 (ja) がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ
HK40034107A (en) Methods for treatment of diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: American Missouri

Applicant after: Galella Laboratories Ltd

Address before: American Missouri

Applicant before: GALERA THERAPEUTICS LLC

COR Change of bibliographic data
GR01 Patent grant
GR01 Patent grant